Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Promethazine
Drug ID BADD_D01854
Description Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.[A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Indications and Usage For the treatment of allergic disorders, and nausea/vomiting.
Marketing Status Prescription; Discontinued
ATC Code D04AA10; R06AD02
DrugBank ID DB01069
KEGG ID D00494
MeSH ID D011398
PubChem ID 4927
TTD Drug ID D0T2XU
NDC Product Code 65162-678; 54348-117
Synonyms Promethazine | Prometazin | Proazamine | Rumergan | Diprazin | Isopromethazine | Phenergan | Phenargan | Phensedyl | Pipolfen | Pipolphen | Promet | Promethazine Hydrochloride | Hydrochloride, Promethazine | Prothazin | Pyrethia | Remsed | Atosil | Diphergan
Chemical Information
Molecular Formula C17H20N2S
CAS Registry Number 60-87-7
SMILES CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Thrombocytosis01.08.02.0010.002785%Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus04.04.01.002; 17.04.07.0040.002785%
Torticollis17.01.03.003; 15.05.04.003--Not Available
Tremor17.01.06.0020.016708%
Unresponsive to stimuli17.02.05.0310.004177%Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.0110.004177%
Urticaria23.04.02.001; 10.01.06.0010.013923%
Venous thrombosis24.01.01.008--Not Available
Vertigo17.02.12.002; 04.04.01.0030.005569%
Vision blurred17.17.01.010; 06.02.06.0070.011138%
Vomiting07.01.07.0030.016708%
Withdrawal syndrome08.06.02.012; 19.07.02.0050.002785%Not Available
Mental status changes19.07.01.0010.004177%Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Emotional distress19.04.02.0080.006962%Not Available
Neonatal hypoxia22.11.02.002; 18.04.15.0020.001453%Not Available
Staphylococcal bacteraemia11.02.05.0010.006962%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Nerve injury17.02.10.007; 12.01.12.002--Not Available
Musculoskeletal stiffness15.03.01.0050.002785%Not Available
Affect lability19.04.01.0010.002785%Not Available
Pulmonary mass22.02.07.0040.009746%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.002785%
Major depression19.15.01.0030.004177%Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.006962%Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages